Cytocom receives FDA clearance of IND for Phase 2 clinical trial of CYTO-205 as treatment for COVID-19

Cytocom receives FDA clearance of IND for Phase 2 clinical trial of CYTO-205 as treatment for COVID-19

FORT COLLINS -- Cytocom, Inc. announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for a Phase 2 clinical trial to evaluate the safety... Read More

Thursday March 18, 2021 0 comments Tags: Fort Collins, Cytocom, CYTO-205, Michael Handley, FDA

Cytocom updates investigational new drug application for phase 2 clinical trial of CYTO-205 for treatment of COVID-19

Cytocom updates investigational new drug application for phase 2 clinical trial of CYTO-205 for treatment of COVID-19

FORT COLLINS -- Cytocom, Inc. today provided an update regarding its CYTO-200 portfolio of clinical programs. Cytocom said it has submitted an Investigational New Drug (IND) application with... Read More

Tuesday February 16, 2021 0 comments Tags: Fort Collins, Cytocom, COVID-19, CYTO-205, Michael Handley